{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-345807","form_type":"8-K","ticker":"AVLN","cik":"0001540171","company_name":"Avalyn Pharma Inc.","filed_at":"2026-08-12T12:06:35+00:00","discovered_at":"2026-08-12T12:10:13.324108+00:00","generated_at":"2026-08-12T12:10:24.322086+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalyn reports Q2 net loss $28.9M; completes MIST enrollment with 398 patients","bullets":["Net loss $28.9M in Q2 2026 vs $20.2M in Q2 2025; R&D $24.7M, G&A $6.6M.","Cash, equivalents, marketable securities $413.5M at June 30, 2026; runway into 2029.","MIST Phase 2b fully enrolled with 398 patients (target 375); topline data expected H2 2027.","AURA Phase 2 enrollment on track (160 patients); topline late 2027; AP03 Phase 1 to start by end 2026.","May 2026 IPO raised ~$316.6M in net proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-345807","json":"https://secwatch.observer/filing/0001193125-26-345807.json","markdown":"https://secwatch.observer/filing/0001193125-26-345807.md","text":"https://secwatch.observer/filing/0001193125-26-345807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/0001193125-26-345807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T12:10:24.322086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}